肥胖相关性心房颤动的研究进展

摘要/Abstract

摘要： 肥胖与心房颤动联系紧密,一些流行病学数据表明,肥胖患者发生心房颤动的可能性更大,肥胖引起的心外膜脂肪增加、全身炎症和氧化应激反应可诱发心房扩大、炎症激活、局部心肌纤维化和电传导异常,这些都可导致心房颤动的发生。肥胖个体的解剖和生理变化可能影响药物的药代动力学特性。减重降低了心房颤动的风险并逆转了心房颤动的自然进展。促使临床医生在心房颤动患者的治疗中纳入体重管理干预措施。我们将肥胖和房颤的流行病学,肥胖引发房颤的机制,肥胖对房颤患者抗心律失常药代动力学的影响,减重如何改善房颤的预后进行了综述。

关键词: 肥胖, 心房颤动, 炎症反应, 心外膜脂肪, 减重

吴兆琦, 许涵, 张玉秀, 陈敏, 刘玲, 陈永清. 肥胖相关性心房颤动的研究进展[J]. 心血管病防治知识, 2024, 14(19): 141-144.

参考文献

[1] Saxton JM, Pickering K, Wane S, et al.Co-designed weight management intervention for women recovering from oestrogen-receptor positive breast cancer[J]. BMC Cancer. 2022;22(1):1202.
[2] Finkelstein EA, Khavjou OA, Thompson H, et al.Obesity and severe obesity forecasts through 2030[J]. Am J Prev Med, 2012,42:563-70.
[3] Jensen MD, Ryan DH, Apovian CM, et al.2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society[J]. J Am Coll Cardiol, 2014, 63(25 Pt B): 2985-3023.
[4] Shu H, Cheng J, Li N, et al.Obesity and atrial fibrillation: a narrative review from arrhythmogenic mechanisms to clinical significance[J]. Cardiovasc Diabetol, 2023,22(1):192.
[5] Verma S, Butler J, Borlaug BA, et al.Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program[J]. J Am Coll Cardiol,2024, 84(17):1603-1614.
[6] Powell-Wiley TM, Poirier P, Burke LE, et al.Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association[J]. Circulation, 2021,143(21):e984-e1010.
[7] Wong CX, Sullivan T, Sun MT, et al.Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies[J]. JACC Clin Electrophysiol, 2015,1:139-152.
[8] Wang TJ, Parise H, Levy D, et al.Obesity and the risk of new-onset atrial fbrillation[J]. JAMA, 2004,292:2471-24777.
[9] Chang G, Chen Y, Liu Z, et al.The PD-1 with PD-L1 Axis is pertinent with the Immune Modulation of Atrial Fibrillation by regulating T cell excitation and promoting the secretion of infammatory factors[J]. J Immunol Res, 2022,2022:3647817.
[10] Li X, Peng S, Wu X, et al.C-reactive protein and atrial fibrillation: Insights from epidemiological and Mendelian randomization studies[J]. Nutr Metab Cardiovasc Dis, 2022,32(6):1519-1527.
[11] Zhang H, Dhalla NS.The Role of Pro-Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease[J]. Int J Mol Sci,2024,25(2):1082.
[12] Stanciu AE, Vatasescu RG, Stanciu MM, et al.The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation[J].Cytokine, 2018,103:63-68.
[13] Liu Y, Wu F, Wu Y, et al.Mechanism of IL-6-related spontaneous atrial fbrillation after coronary artery grafting surgery: IL-6 knockout mouse study and human observation[J]. Transl Res,2021,233:16-31.
[14] Monti CB, Codari M, De Cecco CN, et al.Novel imaging biomarkers: epicardial adipose tissue evaluation[J]. Br J Radiol, 2020,93:20190770.
[15] Malagù M, Tonet E, Orazio G, et al.Association between Epicardial Adipose Tissue and Atrial Fibrillation in Patients with Transfusion-Dependent β-Thalassemia[J]. J Clin Med, 2024,13(12):3471.
[16] Iacobellis G.Epicardial adipose tissue in contemporary cardiology[J]. Nat. Rev. Cardiol, 2022,19:593-606.
[17] Shaihov-Teper O, Ram E, Ballan N, et al.Extracellular vesicles from Epicardial Fat facilitate Atrial Fibrillation[J]. Circulation, 2021,143:2475-2493.
[18] Gerculy R, Benedek I, Kovács I, et al.CT-Assessment of Epicardial Fat Identifies Increased Inflammation at the Level of the Left Coronary Circulation in Patients with Atrial Fibrillation[J]. J Clin Med, 2024,13(5):1307.
[19] Sun X, Li X, Jia H, et al.Nuclear factor E2-Related factor 2 mediates oxidative Stress-Induced lipid Accumulation in Adipocytes by increasing adipogenesis and decreasing Lipolysis[J]. Antioxid Redox Signal, 2020,32:173-192.
[20] Ghareghani A, Abbaszadeh S, Takhshid MA. The role of systemic inflammatory indices in predicting atrial fibrillation and its complications: a narrative review[J]. Curr Med Res Opin.2024 Sep 2:1-10.
[21] Ren X, Wang X, Yuan M, et al.Mechanisms and Treatments of Oxidative Stress in Atrial Fibrillation[J]. Curr Pharm Des. 2018; 24:3062-3071.
[22] Jiang XX, Zhang R, Wang HS.Neferine mitigates angiotensin II-induced atrial fibrillation and fibrosis via upregulation of Nrf2/HO-1 and inhibition of TGF-β/p-Smad2/3 pathways. Aging (Albany NY)[J]. 2024;16(10):8630-8644.
[23] Nishinarita R, Niwano S, Niwano H,et al.Canaglifozin suppresses atrial remodeling in a Canine Atrial Fibrillation Model[J].J Am Heart Assoc. 2021;10:e017483.
[24] Shaikh F, Wynne R, Castelino RL, et al.Effect of Obesity on the Use of Antiarrhythmics in Adults With Atrial Fibrillation: A Narrative Review[J]. Clin Cardiol. 2024;47(8):e24336.
[25] Bruno CD, Harmatz JS, Duan SX, et al.Effect of lipophilicity on drug distribution and elimination: Influence of obesity[J]. Br J Clin Pharmacol. 2021;87(8):3197-3205.
[26] Joglar JA, Chung MK, Armbruster AL, et al.2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation. 2024 Jan 2;149(1):e167.
[27] Sha R, Baines O, Hayes A, et al.Impact of Obesity on Atrial Fibrillation Pathogenesis and Treatment Options[J]. J Am Heart Assoc. 2024;13(1):e032277.
[28] Chokesuwattanaskul R, Shah N, Chokesuwattanaskul S, et al.Low-dose Amiodarone Is Safe: A Systematic Review and Meta-analysis[J]. J Innov Card Rhythm Manag. 2020;11(4):4054-4061.
[29] Ligero C, Riera P, El-Amrani A, et al.Impact of Body Mass Index in the Cardioverter Efficacy of Amiodarone in Persistent Atrial Fibrillation[J]. Pharmaceuticals (Basel). 2024;17(6):693.
[30] Ornelas-Loredo A, Kany S, Abraham V, et al.Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs[J]. JAMA Cardiol. 2020;5(1):57-64.
[31] Hashimoto N, Doki K, Kawano S, et al.Increased serum amiodarone concentration in hypertriglyceridemic patients: Effects of drug distribution to serum lipoproteins[J]. Clin Transl Sci. 2022;15(3):771-781.
[32] Dewal RS, Greer-Short A, Lane C, et al.Phospho-ablation of cardiac sodium channel Nav1.5 mitigates susceptibility to atrial fibrillation and improves glucose homeostasis under conditions of diet-induced obesity[J]. Int J Obes (Lond). 2021;45(4):795-807.
[33] Dan GA, Martinez-Rubio A, Agewall S, et al. Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) andEuropean Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) andInternational Society of Cardiovascular Pharmacotherapy (ISCP) [J]. Europace.2018 May 1;20(5):738.
[34] Ward SM, Radke J, Calhoun C, et al.Weight-based versus non-weight-based diltiazem dosing in the setting of atrial fibrillation with rapid ventricular response[J]. Am J Emerg Med. 2020;38(11):2271-2276.
[35] Meulendijks ER, Janssen-Telders C, Hulsman EL, et al.The change of epicardial adipose tissue characteristics and vulnerability for atrial fibrillation upon drastic weight loss[J]. Adipocyte. 2024;13(1):2395565.
[36] Peigh G, Wasserlauf J, Vogel K, et al.Impact of pre-ablation weight loss on the success of catheter ablation for atrial fbrillation[J]. J Cardiovasc Electrophysiol. 2021;32:2097-2104.
[37] Mahajan R, Lau DH, Brooks AG, et al.Atrial Fibrillation and Obesity: Reverse Remodeling of Atrial Substrate With Weight Reduction[J]. JACC Clin Electrophysiol. 2021;7(5):630-641.
[38] López-Domènech S, Martínez-Herrera M, Abad-Jiménez Z, et al.Dietary weight loss intervention improves subclinical atherosclerosis and oxidative stress markers in leukocytes of obese humans[J]. Int J Obes (Lond). 2019;43(11):2200-2209.
[39] Li L, Alonso A, Romaguera D, et al.Effect of an Intensive Lifestyle Intervention on Circulating Biomarkers of Atrial Fibrillation-Related Pathways among Adults with Metabolic Syndrome: Results from a Randomized Trial[J]. J Clin Med. 2024;13(7):2132.
[40] Donnellan E, Wazni OM, Elshazly M, et al.Impact of Bariatric Surgery on Atrial Fibrillation Type. Circ Arrhythm Electrophysiol[J]. 2020;13(2):e007626.
[41] Pathak RK, Middeldorp ME, Meredith M, et al.Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY)[J]. J Am Coll Cardiol. 2015;65(20):2159-2169.
[42] Johansson C, Lind MM, Eriksson M, et al.Weight, height, weight change, and risk of incident atrial fibrillation in middle-aged men and women[J]. J Arrhythm. 2020;36(6):974-981.
[43] Chung MK, Eckhardt LL, Chen LY, et al.Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association[J]. Circulation. 2020;141(16):e750-e772.
[44] Delesie M, Desteghe L, Bertels M, et al.Motivation of overweight patients with atrial fibrillation to lose weight or to follow a weight loss management program: a cross-sectional study. Acta Cardiol[J]. 2021;76(5):494-503.